Drug intelligence / Profile preview

DL5

Development stage: Preclinical
Modality: Small Molecules

Overview

DL5 is a novel small molecule compound designed to target the serotonin type 4 receptor (5-HT4R). It was developed based on PF-04995274, a known high-affinity 5-HT4R ligand and partial agonist. Preclinical studies in mice have shown that DL5 is effective in reducing stress-induced maladaptive behaviors, suggesting its potential as a rapid-acting treatment for mood disorders, including major depressive disorder and other stress-induced psychiatric illnesses. It has also been observed to attenuate large-amplitude AMPA receptor-mediated bursts in the ventral Cornu Ammonis 3 (vCA3) region of the hippocampus.

Targets

HTR4 (5-Hydroxytryptamine receptor 4)

Beyond the preview

Go deeper on DL5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DL5.

Explore the full profile